|
|
Post by tmfbmf on Apr 20, 2021 19:17:31 GMT
TMFBMF: Respectfully, I am interested in why you would seek Healios take on the proxy, and wondering if you also reached out to another board members as well? Kamikaze Just bc they're the largest shareholder of Athersys. The rest of the BOD (besides Hardy and Traub) I'm assuming are in favor of all proposals in the proxy. Healios has a lot more to gain or lose than I do, so I value their take on things. The rest of the Board has the same fiduciary duty as Hardy but they don't really have a significant personal stake. |
|
|
|
Post by kamikaze on Apr 20, 2021 21:52:57 GMT
Thank you for your response!
|
|
|
|
Post by CM kipper007 on Apr 20, 2021 22:06:38 GMT
I asked Hardy about his opinions on the Athersys proxy. Here is his response: Thank you for your message. You are correct that good corporate governance and protecting shareholder interests are important to me. I am supportive of Athersys's proposal to increase the authorized share count from 300 million shares to 600 million shares and Healios will be voting its shares in favor of this proposal. It is important to recognize that this is simply an increase in the shares authorized for issuance if needed by the Company for any purpose in the future - this provides flexibility, it is not immediate shareholder dilution. Regarding your other question, I do not currently believe any directors should be replaced and Healios will be voting its shares in favor of each of the directors at the Annual Meeting. Sincerely, Hardy TS Kagimoto,MD Chairman&CEO Healios=Life Explosion That is great of you to share TMF. Thank you. Can you also share your email to Hardy as well? |
|
|
|
Post by tmfbmf on Apr 20, 2021 22:29:40 GMT
I asked Hardy about his opinions on the Athersys proxy. Here is his response: Thank you for your message. You are correct that good corporate governance and protecting shareholder interests are important to me. I am supportive of Athersys's proposal to increase the authorized share count from 300 million shares to 600 million shares and Healios will be voting its shares in favor of this proposal. It is important to recognize that this is simply an increase in the shares authorized for issuance if needed by the Company for any purpose in the future - this provides flexibility, it is not immediate shareholder dilution. Regarding your other question, I do not currently believe any directors should be replaced and Healios will be voting its shares in favor of each of the directors at the Annual Meeting. Sincerely, Hardy TS Kagimoto,MD Chairman&CEO Healios=Life Explosion That is great of you to share TMF. Thank you. Can you also share your email to Hardy as well? Yup. You'll notice there's one question he didn't address. --- Hi Dr. Kagimoto. I know corporate governance and defending shareholders is important to you. I just read through the Athersys proxy for the annual meeting. My biggest concern is the proposed increase from 300,000 to 600,000 authorized shares. As Athersys' largest shareholder, I'd like to know if you plan to vote with the Board's recommendations for each proposal. Are my concerns unfounded? Are these C-level compensations really justified? Are there any board members you feel should be replaced? Thanks for any insight you can offer. |
|
|
|
Post by CM kipper007 on Apr 21, 2021 2:40:18 GMT
That is great of you to share TMF. Thank you. Can you also share your email to Hardy as well? Yup. You'll notice there's one question he didn't address. --- Hi Dr. Kagimoto. I know corporate governance and defending shareholders is important to you. I just read through the Athersys proxy for the annual meeting. My biggest concern is the proposed increase from 300,000 to 600,000 authorized shares. As Athersys' largest shareholder, I'd like to know if you plan to vote with the Board's recommendations for each proposal. Are my concerns unfounded? Are these C-level compensations really justified? Are there any board members you feel should be replaced? Thanks for any insight you can offer. Thanks again! Yeah, I see where he chose not to answer. |
|
pata
Junior Member
Posts: 52 
|
Post by pata on Apr 24, 2021 3:09:09 GMT
To compare the relative benefits of holding Healios versus Athersys through the TREASURE data readout:
Assume TREASURE is successful, annual sales of MultiStem in Japan is ~$1B, Healios retains 30% profit (per Mizuho analyst), Athersys receives 15% royalty.
If above, Healios would have earnings per share of $300M / 52M = ~$6. With a P/E of 10, that would increase the share price ~3.8x from its current ~$16.
If above, Athersys would have earnings per share of $150M / 215M = ~$0.70. With a P/E of 10, that would increase the share price ~3.8x from its current ~$1.70.
Adusting annual sales or the P/E ratio does not affect relative advantage of one over the other.
Does this sound right?
|
|
|
|
Post by imz72 on Apr 24, 2021 16:39:51 GMT
|
|
|
|
Post by omstem on Apr 26, 2021 3:22:50 GMT
To compare the relative benefits of holding Healios versus Athersys through the TREASURE data readout: Assume TREASURE is successful, annual sales of MultiStem in Japan is ~$1B, Healios retains 30% profit (per Mizuho analyst), Athersys receives 15% royalty. If above, Healios would have earnings per share of $300M / 52M = ~$6. With a P/E of 10, that would increase the share price ~3.8x from its current ~$16. If above, Athersys would have earnings per share of $150M / 215M = ~$0.70. With a P/E of 10, that would increase the share price ~3.8x from its current ~$1.70. Adusting annual sales or the P/E ratio does not affect relative advantage of one over the other. Does this sound right? |
|
|
|
Post by omstem on Apr 26, 2021 3:25:32 GMT
The above is a good point from Pata. But the difference is ATHX retains all rights for the US and rest of the world. Healios has only Japan rights.
If Japan alone has sales close $1B, imagine the potential for the rest of the world.
Thanks.
|
|
|
|
Post by twenty2 on May 7, 2021 6:19:10 GMT
|
|
|
|
Post by imz72 on May 13, 2021 0:32:18 GMT
Ivor Macleod, Chief Financial Officer of Athersys, speaks at the Bank of America Securities 2021 Virtual Health Care Conference, Wednesday, May 12, 2021
|
|
|
|
Post by twenty2 on May 19, 2021 17:28:32 GMT
Post @reddit - linktwenty2 |
|
|
|
Post by jckrdu on May 20, 2021 15:47:06 GMT
Post @reddit - linktwenty2
You have to register and get a Swapcard account to listen. It's free... takes a little bit of time to register.Hardy's comments starting at minute 16 are most impressive: He talks about Athersys' ARDS study where Athersys saw a 50% reduction in mortality for severe ARDS patients. Then... He states that Helios saw that "same type/tendency of efficacy" for both ventilator free days and mortality rate. Sounds like a winner. Let's see the data. |
|
|
|
Post by twenty2 on May 20, 2021 17:14:06 GMT
Thanks, jckrdu! Post @reddit - linkLittle did I know when I woke early this morning before 4:00 am...Out here on the West Coast (Huntington Beach, California USA)...To see this conference session with Hardy/Healios...That it would bring such comfort, and joy!...Long road ahead...Hopefully it continues to get better...We'll See... twenty2 Edit PS. The screenshot of the four session participants (Including Hardy, and Amir Hefni - VP, Global Commercial Head, Cell & Gene Novartis) that appears in my tweet, corresponds with this moment (With Hardy making a exclamation with his hand/fist)...At 12:30...Hardy: "The pain I'm feeling right now"...Physicians, running ARDS clinical studies in Japan are sending e-mail, after e-mail to Hardy wanting to use the product (MultiStem) "right now, TODAY!"... |
|
|
|
Post by imz72 on May 20, 2021 19:14:32 GMT
I've uploaded a recording of the session to YouTube, but took it down later at the request of the conference's organizers. I hope they don't mind these two short excerpts of Hardy talking about ARDS and Treasure.
ARDS:
The Treasure delay: "We were supposed to finish up the stroke study towards the end of last year, but Covid - you know, the second and third wave hit Japan and then the speed of the enrollment delayed quite significantly, so we are waiting for the last few patients, and it's been quite painful, but now we are finishing up. So I would say there was about 3 to 6 months delay.
|
|
|
|
Post by jckrdu on May 22, 2021 0:43:54 GMT
I've uploaded a recording of the session to YouTube, but took it down later at the request of the conference's organizers. I hope they don't mind these two short excerpts of Hardy talking about ARDS and Treasure. ARDS:
The Treasure delay: "We were supposed to finish up the stroke study towards the end of last year, but Covid - you know, the second and third wave hit Japan and then the speed of the enrollment delayed quite significantly, so we are waiting for the last few patients, and it's been quite painful, but now we are finishing up. So I would say there was about 3 to 6 months delay. Good Luck to Hardy with the Ministry of HealthImz - Thanks for keeping these short video excerpts up. All - While most have seen these videos and they've been discussed at length here and elsewhere, its important to note that Hardy's ARDS strategy (discussed at minute 1:00 of the above ARDS video), is to " file an NDA for Overall ARDS... not limited to pneumonia induced ARDS or Covid-19 induced ARDS". Some may have missed that important point, so I'm just repeating it for emphasis. This plan to file for "Overall" ARDS speaks to the likely strength of the data (as Hardy has already told us), because Hardy only ran the trial in Japan for pneumonia induced ARDS (N=30) and Covid induced ARDS (N=5). Hardy must see results that - in his view and in combination with Athersys overall ARDS results in the USA - justify the Ministry of Health's approval for Overall ARDS in Japan GL Hardy! |
|
|
|
Post by jckrdu on May 22, 2021 11:37:30 GMT
Twenty2 - Many thanks for all your recent posts and content here. Getting timely new information helps all of us, and your posts have made a big contribution. Thanks for all you’re doing.
|
|
|
|
Post by tmfbmf on May 22, 2021 18:54:15 GMT
I like Athersys being a straight forward company when it comes to PRing results. They don't try to spin. If they fail to meet end points, they put it in the headline. Other companies have credibility problems (MESO, CYDY) because of this and the FDA has a long memory. They probably shouldn't take a company's culture and history into account when deciding whether or not to approve a drug/treatment but they do. I worked a lot of years on FDA clinical trials (not stem cells) and Athersys always seemed to do things the right way. Gil had a good relationship with the FDA and I believe we'll see dividends from that soon. I think that's why they gave us mRs shift as a primary end point in the SPA stroke study. (It's not the shift from the last study. There is no arbitrary end point. It's a layup.)
Anyway, all that being said, I'm glad Hardy, not ATHX, is the one who will release the headline for the ARDS study. He'll make it clear that the study showed good results and they are applying for approval. Being such a small study, the probability of hitting an end point is miniscule. I think the results are delayed a bit because he wants to include something about the PMDA in the press release. He knows vultures like AF are circling and won't give them the opportunity to dine.
|
|
|
|
Post by CM kipper007 on May 22, 2021 19:14:17 GMT
Twenty2 - Many thanks for all your recent posts and content here. Getting timely new information helps all of us, and your posts have made a big contribution. Thanks for all you’re doing. Thanks to everyone here on this board. Everyone tries to contribute in a positive way, even if they are coming with criticism or praise. |
|
|
|
Post by twenty2 on May 23, 2021 5:05:31 GMT
Twenty2 - Many thanks for all your recent posts and content here. Getting timely new information helps all of us, and your posts have made a big contribution. Thanks for all you’re doing. Thanks to everyone here on this board. Everyone tries to contribute in a positive way, even if they are coming with criticism or praise. Thanks, jckrdu...I appreciate it!...and, all that you do, as well as so many others here, and elsewhere...If we're not here to help each other, what are we here for? (Help, as best we can, when we can)...It's my philosophy in life...We're all here to help...and, here in particular (at this wonderful site that jham has created - Hello, jham...Hope you're doing well, and staying safe) to help each other better understand our investment in Athersys... Couple of things are on my mind right now...I really thought it was great of you guys to take the High Road in your reaction regarding the passing of Gary Rabin that imz reported on here - link ...You guys are too classy for that...It would be beneath you to do otherwise...There were only a few reactions...Sometimes, no reaction is better than many sorry reactions...Reactions that do no good at all...You don't want to hear me go on, and on with stories...And, it's a little too painful for me...It's water under the bridge...(Learn from the past...Just don't dwell on it longer than necessary) So, I'll keep it short...Good or bad, right or wrong...Bottom line, Gary Rabin, a father, died much too young...Rest In Peace, Gary... The other thing on my mind deals with our investment in Athersys...It's so hard to believe our current share price - $1.66...Why is that you think?...Is the request for an additional 300 million shares keeping a lid on things?...Is our science (Multistem) still considered by many, much unproven?...No proven/experienced CEO at the helm at present?...Is the search for a new CEO in earnest?...Does our management team give away too many free shares, and too many bonuses?...And, or, are we in the mist of some type of manipulation just before someone swoops in to try to buy us out?...I can see the headline now...Fill in the blank, fill in the name _______________ ...Pretend you're a CEO of a biotech name...What's your best offer for all of Athersys???...Do you agree, $5.00 per share would be a steal???...What's the valuation at $5.00?...That's your que, imz...Just teasin'  I'll take a stab, from memory...Roughly 222 Million Shares (I remember 2's real well) X $5.00 = $1.110 Billion... What would the HEADLINE be??? " Athersys Offered 300% Premium For Buyout...Over One Billion Dollars!"...Oh My God! Would you sell?...At present, do you think your fill in the blank biotech could tender the necessary shares (50%+) to complete the deal???...At $5.00?...But, before all this...Are you confident our ATHX board would ever consider this???...At $5.00?...I remember my Dad would always say..."No harm in listening"...Okay, how would the BOD respond?...If the BOD made a counter offer, I wonder what it would be???...$8.50 X 222 M Shares = $1.887 Billion... " Athersys Offered Over 500% Premium For Buyout...Near 2 Billion Dollars!"...Oh My Double God!...Would you sell/tender your shares then???... (Reminder - I believe the valuation of our Ocata, when it was bought out at $8.50, was roughly $376 Million...) What am I getting at?...I spent a good amount of time in the wee hours last night reviewing this thread, - "Appraisal Rights Discussion Thread" (Astellas buys Ocata) link - (14 pages, First Post - Feb 10, 2016 at 7:45am... Last Post - Oct 20, 2018 at 3:40pm...roughly 33 months...Between 2.5 - 3.0 years)... I have so much respect and admiration for what you/those guys did, with the leadership of "vzveteran", and others, and the hero duties of "kukkido"...What a team you all were!... Are you winner rebels all sworn to secrecy?...I have so much to ask!... It could come in handy?...But Most Important, I Want Fill In The Blank Biotech To Know ATHX Shareholders Are No Dummies! We've Been Through This All Before!...I WANT TO BROADCAST IT!...FAR & WIDE... I'll leave it there for now... Best Wishes... twenty2 PS. And, jckrdu...Yes!...I agree..."As Gary Rabin (RIP) would say, I think we've got a tiger by the tail here. "... That's Some Tiger! His Name is MultiStem!
Know His Value... |
|
